Copanlisib
- TRADE NAME: Aliqopa (Bayer)
- INDICATIONS: Relapsed follicular lymphoma in adult patients who have received at least two prior systemic therapies
- CLASS: Kinase inhibitor, Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
- HALF-LIFE: 39 hours
FDA APPROVAL DATE: 09/14/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, Danoprevir, Diltiazem, Elvitegravir, Enzalutamide, Grapefruit Juice, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mitotane, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A4 inducers or inhibitors, Tipranavir, Troleandomycin, Voriconazole
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 02/16/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric